Skip to main content
. 2016 Mar 21;5(3):e211. doi: 10.1038/oncsis.2016.25

Figure 1.

Figure 1

The 3E10 antibody inhibits ErbB2 signaling and cell growth in ErbB2-overexpressing breast cancer cell lines. (a) Coimmunoprecipitation assay examining the ability of 100 nM of control IgG or 3E10 to disrupt the formation of ligand-independent ErbB2-containing heterodimers in BT-474 cells. (b) Coimmunoprecipitation assay detecting EGF-induced ErbB2/EGFR and HRG-induced ErbB2/ErbB3 heterodimerization in BT-474 cells pretreated with 100 nM of control IgG or 3E10. (c) Immunoblots assessing ErbB2 signaling in BT-474 cells upon treatment with 100 nM of control IgG or 3E10 in the absence of ErbB ligand. (d) Immunoblots evaluating the effects of 100 nM of control IgG or 3E10 pretreatment on EGF- or HRG-activated ErbB2 signaling in BT-474 cells. (e and f) MTS assay examining the effects of 100 nM of control IgG or 3E10 on breast cancer cell proliferation in the absence or presence of ErbB ligand (EGF or HRG). Results are shown as percentage of control cell proliferation. Error bars, s.d. *P<0.05, **P<0.001.